NCT03993613View on ClinicalTrials.gov

Apotransferrin in Patients With β-thalassemia

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 21, 2019

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
β-thalassemia Intermedia
Interventions
BIOLOGICAL

human apotransferrin

Intravenous infusions

Trial Locations (1)

1100 DD

Academic Medical Centre, Amsterdam-Zuidoost

Sponsors
All Listed Sponsors
lead

Prothya Biosolutions

INDUSTRY

NCT03993613 - Apotransferrin in Patients With β-thalassemia | Biotech Hunter | Biotech Hunter